Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Oncolytics Biotech Doses First Patient in Pelareorep-anti-PD-1 Study for Breast Cancer

americanpharmaceuticalreviewAugust 27, 2020

Tag: Breast Cancer , Oncolytics , TNBC , pelareorep

PharmaSources Customer Service